Problem is she has not shown to make any good deal besides with herself . Her ability to make deals which are good for SH in general are still to be tested and have no inherent value unless proven .
If you look closely at what Merck is doing that dstock was pointing out you can see they are having great results when getting DCs into the picture by activating them better with TLR-7/8agonists. So what does that tell you not only about DCVax-L’s role but more importantly what improved Direct will be able to do. The approval of L gets eyes immediately on Direct. The value of that is being validated by what Merck is experiencing with their combo trials now. Bottom line is partnerships save big pharma and others with potential combos which provides a slower economic transition for many and prevents an all out bidding war for rights to Direct. Best wishes.
Market Data 
Markets 
AI
